Prolong Pharmaceuticals

Prolong Pharmaceuticals is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing differentiated products that address unmet medical needs. The company is currently developing a portfolio of products in stroke, hematology, and oncology. Its lead asset, PP-007 (SANGUINATEā„¢), addresses disorders involving ischemia, hypoxia, and/or hemolysis.

Sign up for our newsletter

© All rights reserved Tarsadia